Persistence of pharmacological migraine prevention based on statutory health insurance claims data from Germany: A retrospective cohort study
Abstract
Abstract Backround In the global population aged 20–99 years, migraine shows the second greatest loss of disability-adjusted life years (DALYs). In Germany, migraine affects around 15% of all women and 6% of all men. Migraine preventive therapy aims to reduce the frequency, severity and duration of attacks. We evaluated the persistence of conventional drug therapies for migraine prevention under real-world conditions focusing on defined oral drugs and Clostridium botulinum neurotoxin type A (BoNTA) in patients who were subsequently prescribed aCGRP monoclonal antibodies. Methods Claims data from German statutory health insurance were used to analyze prescription patterns. Prevalent migraine patients were defined as individuals over 18 years of age at the beginning of the observation period with at least one ICD-10 G43 diagnosis. Persistence of oral prophylactic therapies and BoNTA was determined retrospectively in migraine patients with a first prescription of an aCGRP-mAb between October 1 and December 31, 2021 and uninterrupted retrospective data over the preceding five years. Persistence was defined as 180 days of uninterrupted preventive therapy with the same as the first prescription. Prescription duration was based on the therapeutic range per prescribed package according to the prescribing information. Kaplan-Meier survival analyses were conducted to evaluate the time until treatment discontinuation. Results For the analysis of conventional therapies, a cohort of 137…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 137 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.